SCHEMBL447835

SCHEMBL447835

NC(=O)c1ccc(Cl)cn1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.56
SIRT6 Q8N6T7 2/20 0.55
KMT2A Q03164 1/20 0.53
ADRA2A P08913 2/20 0.47
ADRA2B P18089 2/20 0.47
ADRA2C P18825 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
PLAU P00749 1/20 0.47
PTK2 Q05397 1/20 0.44
LMNA P02545 1/20 0.43
ADORA3 P0DMS8 1/20 0.42
TSHR P16473 1/20 0.42
MC4R P32245 1/20 0.42
ADRA1A P35348 1/20 0.42
MC3R P41968 1/20 0.42
MAP4K4 O95819 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3493985 0.98 MAOB (0.54) MAOBSIRT6KMT2AADRA2AADRA2B
Hydrochloric Acid SCHEMBL27870983 0.98 MAOB (0.54) MAOBSIRT6KMT2AADRA2AADRA2B
SCHEMBL25414763 0.86 MAOB (0.53) MAOBSIRT6KMT2AL3MBTL1PTK2
SCHEMBL10815017 0.82 MAOB (0.55) MAOBADRA2AADRA2BADRA2CL3MBTL1
SCHEMBL211889 0.80 P4HTM (0.59) MAOBL3MBTL1MAP4K4
SCHEMBL1441384 0.80 MAOB (0.53) MAOBSIRT6L3MBTL1PTK2NPC1
SCHEMBL11421429 0.80 P2RX3 (0.54) MAOBSIRT6KMT2ARAB9A
SCHEMBL15687801 0.79 MAOB (0.67) MAOBL3MBTL1PTK2LMNANPC1
SCHEMBL14003355 0.79 MAOB (0.49) MAOBSIRT6KMT2AL3MBTL1PTK2
SCHEMBL16465952 0.79 MAOB (0.57) MAOBL3MBTL1PTK2TSHRNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 419 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220402875-A1 S1P3 Antagonists TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) 2022-12-22 US claimed
CN-115210220-A Process for the preparation of 5-chloro-3-alkylsulfanyl-pyridine-2-carboxylic acid amides and formates 先正达农作物保护股份公司 2022-10-18 CN claimed
EP-3484865-B1 SOMATOSTATIN MODULATORS AND USES THEREOF CRINETICS PHARMACEUTICALS INC (US) 2022-09-14 EP claimed
EP-3689864-A1 S1P3 ANTAGONISTS Teva Pharmaceutical Industries Limited (IL) 2020-08-05 EP claimed
US-20200157052-A1 S1P3 Antagonists TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) 2020-05-21 US claimed
EP-3086845-B1 S1P3 ANTAGONISTS TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) 2019-11-20 EP claimed
US-20180201582-A1 S1P3 ANTAGONISTS TEVA PHARMACEUTICAL INDUSTRIES LIMITED (IL) 2018-07-19 US claimed
EP-3218365-A1 2-AMINO-6-(DIFLUOROMETHYL)- 5,5-DIFLUORO-6-PHENYL-3,4,5,6-TETRAHYDROPYRIDINES AS BACE1 INHIBITORS H. Lundbeck A/S (DK) 2017-09-20 EP claimed
EP-3086845-A1 S1P3 ANTAGONISTS Teva Pharmaceutical Industries Limited (IL) 2016-11-02 EP claimed
US-20160297762-A1 S1P3 ANTAGONISTS TEVA PHARMACEUTICAL INDUSTRIES LIMITED (IL) 2016-10-13 US claimed
US-20040110778-A1 Heterocyclic compounds as ligands of the GABAA receptor YOHANNES DANIEL (US) 2004-06-10 US claimed
US-20040067939-A1 Indole-3-carboxamides as glucokinase activators CORBETT WENDY LEA (US) 2004-04-08 US claimed
US-6673811-B1 TREATMENT OF ANXIETY, DEPRESSION, SLEEP DISORDER, ATTENTION DEFICIT DISORDER, ALZHEIMER'S DEMENTIA, OR SHORT-TERM MEMORY LOSS NEUROGEN CORPORATION 2004-01-06 US claimed
WO-2003099276-A1 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-12-04 WO claimed
EP-1325006-A2 HETEROCYCLIC COMPOUNDS AS LIGANDS OF THE GABA A? RECEPTOR NEUROGEN CORPORATION (US) 2003-07-09 EP claimed
US-20030105081-A1 Heterocyclic compounds as ligands of the GABAA receptor PFIZER INC 2003-06-05 US claimed
WO-2003044018-A1 1H-PYRROLO[3,2-B]PYRIDINE-3-CARBOXYLIC ACID AMIDES NEUROGEN CORPORATION (US) 2003-05-30 WO claimed
WO-2002028353-A2 PHOSPHATE TRANSPORT INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2002-04-11 WO claimed
WO-2002012442-A2 HETEROCYCLIC COMPOUNDS AS LIGANDS OF THE GABAA RECEPTOR NEUROGEN CORPORATION (US) 2002-02-14 WO claimed
EP-0341081-B1 Novel amino acid derivatives ONO PHARMACEUTICAL CO (JP) 1995-07-05 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105081-A1 Heterocyclic compounds as ligands of the GABAA receptor GABRB1, GABRP, GABRA1 MAOB 286/4885SIRT6 2421/4885KMT2A 2120/4885
US-20040067939-A1 Indole-3-carboxamides as glucokinase activators GCKR, GPR119, GCK MAOB 1128/4885SIRT6 122/4885KMT2A 1881/4885
US-20180201582-A1 S1P3 ANTAGONISTS S1PR3, S1PR5, S1PR1 MAOB 1637/4885SIRT6 1839/4885KMT2A 2731/4885
US-20160297762-A1 S1P3 ANTAGONISTS S1PR3, S1PR5, S1PR1 MAOB 1637/4885SIRT6 1839/4885KMT2A 2731/4885
US-20220402875-A1 S1P3 Antagonists S1PR3, S1PR5, S1PR1 MAOB 1637/4885SIRT6 1839/4885KMT2A 2731/4885
US-20200157052-A1 S1P3 Antagonists S1PR3, S1PR5, S1PR1 MAOB 1637/4885SIRT6 1839/4885KMT2A 2731/4885
US-20040110778-A1 Heterocyclic compounds as ligands of the GABAA receptor GABRB1, GABRP, GABRA1 MAOB 286/4885SIRT6 2421/4885KMT2A 2120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.